Description

Simple

Clinical

Overview

Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.

Pharmacology

Indication

For the treatment of hypertension.

Pharmacodynamic

Manidipine produces vasodilation resulting in lower blood pressure [1].

Mechanism of action

Contraction of vascular smooth muscle is stimulated by Gq coupled receptors which produce calcium release from the sarcoplasmic reticulum. This is followed by opening of voltage dependent calcium channels and an influx of calcium into the cell ultimately producing contraction. Manidipine binds to an... Read more

Absorption

The median Tmax is 1.5 h [1]. Administration with food produces an 1.3-1.6-fold increase in Cmax but no change in Tmax. Manidipine does not... Read more

Protein binding

Manidipine is 99% bound to human plasma proteins [1].

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

The half life of elimination has been observed to be dose dependent [1]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7... Read more

Route of elimination

Manidipine is eliminated through extensive metabolism. 63% is eliminated in the feces and 31% in the urine as metabolites [1].

Toxicity

The most common adverse events reported in clinical trials were ankle oedema (6%), headache (3.8%), palpitation (2.7%), flushing (2.2%), dizziness (1.6%), rash (0.5%) and fatigue (0.5%) [ Read more

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Manidipine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Manidipine.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Manidipine.
1-benzylimidazole
1-benzylimidazole may decrease the antihypertensive activities of Manidipine.
2,4-thiazolidinedione
The risk or severity of hypoglycemia can be increased when Manidipine is combined with 2,4-thiazolidinedione.
2,5-Dimethoxy-4-ethylamphetamine
2,5-Dimethoxy-4-ethylamphetamine may decrease the antihypertensive activities of Manidipine.
2,5-Dimethoxy-4-ethylthioamphetamine
2,5-Dimethoxy-4-ethylthioamphetamine may decrease the antihypertensive activities of Manidipine.
4-Bromo-2,5-dimethoxyamphetamine
4-Bromo-2,5-dimethoxyamphetamine may decrease the antihypertensive activities of Manidipine.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be decreased when combined with Manidipine.
4-Methoxyamphetamine
The metabolism of 4-Methoxyamphetamine can be decreased when combined with Manidipine.
5-methoxy-N,N-dimethyltryptamine
The metabolism of Manidipine can be decreased when combined with 5-methoxy-N,N-dimethyltryptamine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Manidipine.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be decreased when combined with Manidipine.
Abafungin
The therapeutic efficacy of Abafungin can be increased when used in combination with Manidipine.
Abediterol
Abediterol may decrease the antihypertensive activities of Manidipine.
Acarbose
The risk or severity of hypoglycemia can be increased when Manidipine is combined with Acarbose.
Acebutolol
The metabolism of Acebutolol can be decreased when combined with Manidipine.
Aceclofenac
The therapeutic efficacy of Manidipine can be decreased when used in combination with Aceclofenac.
Acemetacin
The therapeutic efficacy of Manidipine can be decreased when used in combination with Acemetacin.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Manidipine.
Acepromazine
The risk or severity of hypotension can be increased when Acepromazine is combined with Manidipine.
2 References
  1. 1 . Cheer SM, McClellan K: Manidipine: a review of its use in hypertension. Drugs. 2001;61(12):1777-99.PubMed: 11693466
  2. 2 . McKeage K, Scott LJ: Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64(17):1923-40.PubMed: 15329044